Dhillon Sohita, Yang Lily P H, Curran Monique P
Wolters Kluwer Health Adis, Auckland, New Zealand.
CNS Drugs. 2008;22(7):613-7. doi: 10.2165/00023210-200822070-00006.
Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL/Wellbutrin XR] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion. Oral three-times-daily bupropion IR was effective and generally well tolerated in the treatment of major depressive disorder (MDD). It was as efficacious and as well tolerated as some TCAs and the SSRI fluoxetine. Moreover, it was associated with less somnolence and weight gain than some TCAs. Twice-daily bupropion SR was also efficacious and generally well tolerated in the treatment of MDD. It was as effective as and had a generally similar tolerability profile to some SSRIs, but had the advantage of less somnolence and sexual dysfunction. The efficacy of bupropion XR in terms of primary efficacy measures was established in two of six well designed placebo-controlled studies. Bupropion XR also demonstrated efficacy in terms of some secondary outcomes in five of these studies. Additionally, bupropion XR was similar, in terms of the primary efficacy outcomes, to the SSRI escitalopram in two placebo-controlled trials and to the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine extended release (XR) in two trials (one of which was placebo-controlled), but not in a third placebo-controlled trial where venlafaxine XR was better than bupropion XR. It was generally as well tolerated as escitalopram and venlafaxine XR, but was associated with less sexual dysfunction than escitalopram. Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.
安非他酮被认为是一种多巴胺 - 去甲肾上腺素再摄取抑制剂,是一种有效的抗抑郁药。它有三种口服剂型:(i)安非他酮速释片(IR)[安非他酮],每日服用三次;(ii)安非他酮缓释片(SR)[安非他酮缓释片],每日服用两次;(iii)安非他酮长效/缓释片(XR)[安非他酮长效片/安非他酮缓释片],每日服用一次。就安非他酮的全身暴露而言,这三种剂型具有生物等效性。每日三次口服的安非他酮速释片在治疗重度抑郁症(MDD)方面有效且通常耐受性良好。它与某些三环类抗抑郁药和选择性5-羟色胺再摄取抑制剂(SSRI)氟西汀一样有效且耐受性良好。此外,与某些三环类抗抑郁药相比,它导致的嗜睡和体重增加较少。每日两次服用的安非他酮缓释片在治疗MDD方面也有效且通常耐受性良好。它与某些SSRI一样有效,耐受性总体相似,但具有嗜睡和性功能障碍较少的优势。在六项精心设计的安慰剂对照研究中的两项中确定了安非他酮长效片在主要疗效指标方面的疗效。在其中五项研究中,安非他酮长效片在一些次要结局方面也显示出疗效。此外,在两项安慰剂对照试验中,就主要疗效结局而言,安非他酮长效片与SSRI艾司西酞普兰相似,在两项试验(其中一项为安慰剂对照)中与5-羟色胺 - 去甲肾上腺素再摄取抑制剂(SNRI)文拉法辛缓释片(XR)相似,但在第三项安慰剂对照试验中,文拉法辛缓释片比安非他酮长效片效果更好。它的耐受性总体上与艾司西酞普兰和文拉法辛缓释片相似,但与艾司西酞普兰相比,性功能障碍较少。现有临床数据表明,安非他酮是治疗MDD的一种有效且通常耐受性良好的选择,新剂型具有减少每日给药次数的优势。